ReviewNeuromodulation : journal of the International Neuromodulation Society2022
Biomarkers for Deep Brain Stimulation in Animal Models of Depression.
Review in Neuromodulation : journal of the International Neuromodulation Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Low-Cost Modular Multi-Region Electrode for Distributed Network Recording and Brain State Decoding.Brain sciences · 2026Article
- What factors influence the length of stay and readmission after deep brain stimulation surgery? a tertiary centre study.Acta neurochirurgica · 2026Article
- γ neuromodulations: unraveling biomarkers for neurological and psychiatric disorders.Military Medical Research · 2025Review
- Resolution of tonic concentrations of highly similar neurotransmitters using voltammetry and deep learning.Molecular psychiatry · 2024Article
- Brain near-infrared study of upstairs movement after anterior cruciate ligament reconstruction.Frontiers in neurology · 2024Article
- Treating addiction with deep brain stimulation: Ethical and legal considerations.The International journal on drug policy · 2023Review
- Cosmetic considerations for placement of deep brain stimulation pulse generator: the submammary subfascial approach.Acta neurochirurgica · 2023Article
- Oxycodone-induced dopaminergic and respiratory effects are modulated by deep brain stimulation.Frontiers in pharmacology · 2023Article
- High frequency deep brain stimulation can mitigate the acute effects of cocaine administration on tonic dopamine levels in the rat nucleus accumbens.Frontiers in neuroscience · 2023Article
- Deep Brain Stimulation for Addictive Disorders-Where Are We Now?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesDespite recent advances in depression treatment, many patients still do not respond to serial conventional therapies and are considered "treatment resistant." Deep brain stimulation (DBS) has therapeutic potential in this context. This comprehensive review of recent studies of DBS for depression in animal models identifies potential biomarkers for improving therapeutic efficacy and predictability of conventional DBS to aid future development of closed-loop control of DBS systems. MATERIALS AND
methodsA systematic search was performed in Pubmed, EMBASE, and Cochrane Review using relevant keywords. Overall, 56 animal studies satisfied the inclusion criteria.
resultsOutcomes were divided into biochemical/physiological, electrophysiological, and behavioral categories. Promising biomarkers include biochemical assays (in particular, microdialysis and electrochemical measurements), which provide real-time results in awake animals. Electrophysiological tests, showing changes at both the target site and downstream structures, also revealed characteristic changes at several anatomic targets (such as the medial prefrontal cortex and locus coeruleus). However, the substantial range of models and DBS targets limits the ability to draw generalizable conclusions in animal behavioral models.
conclusionsOverall, DBS is a promising therapeutic modality for treatment-resistant depression. Different outcomes have been used to assess its efficacy in animal studies. From the review, electrophysiological and biochemical markers appear to offer the greatest potential as biomarkers for depression. However, to develop closed-loop DBS for depression, additional preclinical and clinical studies with a focus on identifying reliable, safe, and effective biomarkers are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.